ENTPD1 and neoplasm: The development of NTPDase1/CD39-based therapies appears particularly relevant in the perspective to inhibiting the NTPDase1/CD39 pathway and the related NK cell-mediated anti-tumor immunity suppression (Zhang et al., 2019).